XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Operating Cash Flow

Cash generated by the company's core business operations during the period.

XOMA Royalty Corp.NASDAQ: XOMA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of $6.04M rose 174.8% year over year, behind the +199.3% change in trailing-twelve-month operating cash flow.

Context

  • Operating cash flow amounted to 5.5% of revenue in FY2025, down 42.8 pp from a year earlier.
  • Operating cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +174.8% toward the trailing-twelve-month pace of +199.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.04M+209.8% QoQ
Last fiscal yearDec 2025
$2.87M+120.9% YoY
LTMMar 2026
$6.63M+199.3% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+174.8%——
1 year+120.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
2.87M USD
Year-over-year change
+120.9%
4-year CAGR
-40.4%

Operating Cash Flow vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's LTM Mar 2026 operating cash flow of $6.63M is the smallest of the 10 companies compared; the peer median is $91.28M.
  • Its year-over-year change of +199.3% is the highest of 10, against a peer median of +13.3%.
  • Operating cash flow amounts to 18.3% of revenue for XOMA, versus a peer median of 2690.8%.
XOMA Competitors Peer median
Operating Cash Flow for XOMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$273.32M +13.3%+36.2%295.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$179.63M -13.9%+2.2%—
SLDBSolid Biosciences Inc.LTM Mar 2026$171.67M +60.9%+16.8%—
QSIQuantum-Si incorporatedLTM Mar 2026$94.2M +3.8%+1.5%5086.4%
AURAAura Biosciences, Inc.LTM Mar 2026$91.28M +16.0%+15.8%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$54M +13.8%+1.9%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$31.05M +37.6%+36.2%—
BNTCBenitec Biopharma Inc.LTM Mar 2026$20.57M +10.2%+14.1%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$20.05M -46.3%-8.4%—
XOMAXOMA Royalty Corp.LTM Mar 2026$6.63M +199.3%—18.3%
Peer median (excluding XOMA) $91.28M+13.3%+14.1%2690.8%

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.8M(17.1M)(40.83M)(13.82M)31.71M
Depreciation & Amortization7K104K900K216K2.97M
Deferred Income Tax000(5.66M)103K
Stock-Based Compensation6.2M3.61M9.1M10.31M9.27M
Change in Working Capital(886K)(181K)(3.53M)(2.79M)(11.37M)
Accounts Receivables1.58M208K(1M)(835K)(2.43M)
Inventory00000
Accounts Payables765K1.85M(523K)1.6M(10.6M)
Other Working Capital(3.23M)(2.23M)(2M)(3.55M)1.65M
Other Non-Cash Items1.56M694K16.2M(2.01M)(29.82M)
Operating Cash Flow22.68M(12.88M)(18.16M)(13.75M)2.87M
Capital Expenditures(26.5M)(15.25M)(17K)(20K)0
Acquisitions (Net)000(1.25M)3.85M
Purchases of Investments000(3.24M)(99K)
Sales of Investments00000
Other Investing Activities(26.5M)(4.97M)(694K)(23.75M)47.14M
Investing Cash Flow(26.5M)(20.22M)(711K)(28.26M)50.89M
Debt Repayment(4.25M)0130M(6.9M)(10.6M)
Common Stock Issued1.58M2.42M466K5.21M8.72M
Common Stock Repurchased00(148K)(13K)(16.04M)
Dividends Paid(3.5M)(5.47M)(5.47M)(5.47M)(5.47M)
Other Financing Activities(21M)(1.4M)(3.79M)1.26M(3.07M)
Financing Cash Flow12.84M(4.45M)120.59M(11.13M)(26.46M)
Effect of Forex Changes00000
Net Change in Cash9.01M(37.55M)101.72M(53.13M)27.29M
Free Cash Flow(3.82M)(28.13M)(18.18M)(13.77M)2.87M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.